Short answer
Pulmonx Corp (LUNG) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $23M (up 6.2% year over year) with net income of −$8M.
Q3 2026 key financials · XBRL
- Revenue
- $23M
- +6.2% YoY · +0.3% QoQ
- Net income
- −$8M
- +39.9% YoY · +16.7% QoQ
- Operating margin
- -32.8%
- Gross margin
- 76.2%
- EPS (diluted)
- −$0.20
- +41.2% YoY · +13.0% QoQ
Source: XBRL data from the Pulmonx Corp (LUNG) Q3 2026 10-Q on SEC EDGAR. USD.
Pulmonx Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $22.8M, up 6.2% YoY from $21.5M, driven by Zephyr Valve procedure volumes
- Gross margin 76.2% vs 74.7% YoY, reflecting geographic mix changes
- U.S. revenue $14.9M vs $14.0M, international revenue $7.9M vs $7.5M
- Cash $52.7M, operating cash outflow $18.5M through nine months, versus $25.3M YoY
- Outlook: cash funding for at least 12 months, continued net losses and substantial additional funding needs expected
Risk Factors
- Newly added cybersecurity risk: January 2025 Intelerad vendor incident, despite no impact to Pulmonx’s LungTraX account or network
- Most material update, trade risk: new U.S. tariffs and retaliatory measures could raise costs, with fixed pricing limiting pass-through for up to 36 months
- Regulatory risk: CMS could establish coverage restrictions through a national or local coverage determination for endobronchial valves
- Operational risk: $40.0 million Perceptive debt introduces covenant-breach risk and potential immediate repayment
- Financial risk: $52.7 million cash and cash equivalents expected to fund operations for at least the next twelve months, subject to estimates
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pulmonx Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.